Participant flow

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.

   id

   FG000

   title

   MLN8237

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible: wrong primary

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible: inadequate pathology

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      STARTED

   2. achievements

      1. comment

         Eligible and treated patients.

         group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was activated on 8/6/2012 and closed to accrual on 6/3/2013.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice